Low levels of pyridoxal 5'-phosphate in patients with cystic fibrosis
Extract: To determine the effect of cystic fibrosis on the regulation of plasma pyridoxal 5'-phosphate (PLP), the biologically active form of vitamin B6, we measured this compound in plasma from 56 patients with cystic fibrosis. The concentration of PLP in plasma was assayed by a radioenzymatic...
Gespeichert in:
| Veröffentlicht in: | Pediatrics (Evanston) 1986-08, Vol.78 (2), p.278-282 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 282 |
|---|---|
| container_issue | 2 |
| container_start_page | 278 |
| container_title | Pediatrics (Evanston) |
| container_volume | 78 |
| creator | Faraj, B.A Caplan, D.B Camp, V.M Pilzer, E Kutner, M |
| description | Extract: To determine the effect of cystic fibrosis on the regulation of plasma pyridoxal 5'-phosphate (PLP), the biologically active form of vitamin B6, we measured this compound in plasma from 56 patients with cystic fibrosis. The concentration of PLP in plasma was assayed by a radioenzymatic technique. The results of this study showed that PLP concentration was decreased significantly (6.44 +/- 5.20 ng/mL, mean +/- SD; median 4.45 ng/mL) in patients with cystic fibrosis as compared with a group of hospitalized children with neither cystic fibrosis nor hepatic disease serving as a control group (13.2 +/- 5.04 ng/mL, mean +/- SD; median 12.5 ng/mL). Additionally, 25% of the population with cystic fibrosis exhibited exceedingly low plasma PLP level (less than 2.75 ng/mL). In patients with cystic fibrosis, significant inverse linear associations were found between plasma PLP1018 and serum levels of SGOT and SGPT (PLP v SGOT: r = -.60, P less than .03; PLP v SGPT: r = -.50, P less than .03). This study demonstrated that a deficiency of plasma PLP is a common abnormality in cystic fibrosis and that the low PLP level may be a reflection of impaired vitamin B6 metabolism associated with this disorder.(aut |
| doi_str_mv | 10.1542/peds.78.2.278 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76972008</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76972008</sourcerecordid><originalsourceid>FETCH-LOGICAL-c338t-6c0a6f458fb36311fb9654ca3846520e81031d83dade65e9f1e4abbe151abba83</originalsourceid><addsrcrecordid>eNo9kM1LwzAYxoMoc06P3hRyED21Js1njzLmBww86M4hTRMX6ZbadM7992asjPfwHN4fDw8_AK4xyjGjxWNr65gLmRd5IeQJGGNUyowWgp2CMUIEZxQhdg4uYvxGCFEmihEYEZEO0TGYzcMWNvbXNhEGB9td5-vwpxvIHrJ2GWK71L2Ffg1b3Xu77iPc-n4JzS723kDnqy5EHy_BmdNNtFdDTsDiefY5fc3m7y9v06d5ZgiRfcYN0txRJl1FOMHYVSVn1GgiKWcFshKnvbUkta4tZ7Z02FJdVRYznEJLMgH3h962Cz8bG3u18tHYptFrGzZRCV6KAqE9mB1Ak_bFzjrVdn6lu53CSO21qb02JaQqVNKW-NuheFOtbH2kB0_pfzf8dTS6cZ1eGx-PmCglLUucsJsD5nRQ-qtLyOJDCsaJxFKSfyYjfkY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76972008</pqid></control><display><type>article</type><title>Low levels of pyridoxal 5'-phosphate in patients with cystic fibrosis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Faraj, B.A ; Caplan, D.B ; Camp, V.M ; Pilzer, E ; Kutner, M</creator><creatorcontrib>Faraj, B.A ; Caplan, D.B ; Camp, V.M ; Pilzer, E ; Kutner, M</creatorcontrib><description>Extract: To determine the effect of cystic fibrosis on the regulation of plasma pyridoxal 5'-phosphate (PLP), the biologically active form of vitamin B6, we measured this compound in plasma from 56 patients with cystic fibrosis. The concentration of PLP in plasma was assayed by a radioenzymatic technique. The results of this study showed that PLP concentration was decreased significantly (6.44 +/- 5.20 ng/mL, mean +/- SD; median 4.45 ng/mL) in patients with cystic fibrosis as compared with a group of hospitalized children with neither cystic fibrosis nor hepatic disease serving as a control group (13.2 +/- 5.04 ng/mL, mean +/- SD; median 12.5 ng/mL). Additionally, 25% of the population with cystic fibrosis exhibited exceedingly low plasma PLP level (less than 2.75 ng/mL). In patients with cystic fibrosis, significant inverse linear associations were found between plasma PLP1018 and serum levels of SGOT and SGPT (PLP v SGOT: r = -.60, P less than .03; PLP v SGPT: r = -.50, P less than .03). This study demonstrated that a deficiency of plasma PLP is a common abnormality in cystic fibrosis and that the low PLP level may be a reflection of impaired vitamin B6 metabolism associated with this disorder.(aut</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.78.2.278</identifier><identifier>PMID: 3737304</identifier><identifier>CODEN: PEDIAU</identifier><language>eng</language><publisher>Elk Grove Village, IL: American Academy of Pediatrics</publisher><subject>Adolescent ; Adult ; ADULTE ; ADULTOS ; Alanine Transaminase - blood ; Aspartate Aminotransferases - blood ; Biological and medical sciences ; Body Height ; Body Weight ; BPYRIDOXINE ; Child ; Child, Preschool ; COMPOSICION DE LA SANGRE ; COMPOSITION DU SANG ; Cystic Fibrosis - blood ; ENFANT ; ENFERMEDADES HEPATICAS ; FIBROMA ; FIBROME ; Follow-Up Studies ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; MALADIE DU FOIE ; MALNUTRICION ; MALNUTRITION ; Medical sciences ; NINOS ; NUTRI ; Other diseases. Semiology ; PIRIDINAS ; PYRIDINE ; Pyridoxal Phosphate - blood ; r)PIRIDOXINA ; Time Factors ; Veins</subject><ispartof>Pediatrics (Evanston), 1986-08, Vol.78 (2), p.278-282</ispartof><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c338t-6c0a6f458fb36311fb9654ca3846520e81031d83dade65e9f1e4abbe151abba83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7984991$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3737304$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Faraj, B.A</creatorcontrib><creatorcontrib>Caplan, D.B</creatorcontrib><creatorcontrib>Camp, V.M</creatorcontrib><creatorcontrib>Pilzer, E</creatorcontrib><creatorcontrib>Kutner, M</creatorcontrib><title>Low levels of pyridoxal 5'-phosphate in patients with cystic fibrosis</title><title>Pediatrics (Evanston)</title><addtitle>Pediatrics</addtitle><description>Extract: To determine the effect of cystic fibrosis on the regulation of plasma pyridoxal 5'-phosphate (PLP), the biologically active form of vitamin B6, we measured this compound in plasma from 56 patients with cystic fibrosis. The concentration of PLP in plasma was assayed by a radioenzymatic technique. The results of this study showed that PLP concentration was decreased significantly (6.44 +/- 5.20 ng/mL, mean +/- SD; median 4.45 ng/mL) in patients with cystic fibrosis as compared with a group of hospitalized children with neither cystic fibrosis nor hepatic disease serving as a control group (13.2 +/- 5.04 ng/mL, mean +/- SD; median 12.5 ng/mL). Additionally, 25% of the population with cystic fibrosis exhibited exceedingly low plasma PLP level (less than 2.75 ng/mL). In patients with cystic fibrosis, significant inverse linear associations were found between plasma PLP1018 and serum levels of SGOT and SGPT (PLP v SGOT: r = -.60, P less than .03; PLP v SGPT: r = -.50, P less than .03). This study demonstrated that a deficiency of plasma PLP is a common abnormality in cystic fibrosis and that the low PLP level may be a reflection of impaired vitamin B6 metabolism associated with this disorder.(aut</description><subject>Adolescent</subject><subject>Adult</subject><subject>ADULTE</subject><subject>ADULTOS</subject><subject>Alanine Transaminase - blood</subject><subject>Aspartate Aminotransferases - blood</subject><subject>Biological and medical sciences</subject><subject>Body Height</subject><subject>Body Weight</subject><subject>BPYRIDOXINE</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>COMPOSICION DE LA SANGRE</subject><subject>COMPOSITION DU SANG</subject><subject>Cystic Fibrosis - blood</subject><subject>ENFANT</subject><subject>ENFERMEDADES HEPATICAS</subject><subject>FIBROMA</subject><subject>FIBROME</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>MALADIE DU FOIE</subject><subject>MALNUTRICION</subject><subject>MALNUTRITION</subject><subject>Medical sciences</subject><subject>NINOS</subject><subject>NUTRI</subject><subject>Other diseases. Semiology</subject><subject>PIRIDINAS</subject><subject>PYRIDINE</subject><subject>Pyridoxal Phosphate - blood</subject><subject>r)PIRIDOXINA</subject><subject>Time Factors</subject><subject>Veins</subject><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1LwzAYxoMoc06P3hRyED21Js1njzLmBww86M4hTRMX6ZbadM7992asjPfwHN4fDw8_AK4xyjGjxWNr65gLmRd5IeQJGGNUyowWgp2CMUIEZxQhdg4uYvxGCFEmihEYEZEO0TGYzcMWNvbXNhEGB9td5-vwpxvIHrJ2GWK71L2Ffg1b3Xu77iPc-n4JzS723kDnqy5EHy_BmdNNtFdDTsDiefY5fc3m7y9v06d5ZgiRfcYN0txRJl1FOMHYVSVn1GgiKWcFshKnvbUkta4tZ7Z02FJdVRYznEJLMgH3h962Cz8bG3u18tHYptFrGzZRCV6KAqE9mB1Ak_bFzjrVdn6lu53CSO21qb02JaQqVNKW-NuheFOtbH2kB0_pfzf8dTS6cZ1eGx-PmCglLUucsJsD5nRQ-qtLyOJDCsaJxFKSfyYjfkY</recordid><startdate>19860801</startdate><enddate>19860801</enddate><creator>Faraj, B.A</creator><creator>Caplan, D.B</creator><creator>Camp, V.M</creator><creator>Pilzer, E</creator><creator>Kutner, M</creator><general>American Academy of Pediatrics</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19860801</creationdate><title>Low levels of pyridoxal 5'-phosphate in patients with cystic fibrosis</title><author>Faraj, B.A ; Caplan, D.B ; Camp, V.M ; Pilzer, E ; Kutner, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c338t-6c0a6f458fb36311fb9654ca3846520e81031d83dade65e9f1e4abbe151abba83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>ADULTE</topic><topic>ADULTOS</topic><topic>Alanine Transaminase - blood</topic><topic>Aspartate Aminotransferases - blood</topic><topic>Biological and medical sciences</topic><topic>Body Height</topic><topic>Body Weight</topic><topic>BPYRIDOXINE</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>COMPOSICION DE LA SANGRE</topic><topic>COMPOSITION DU SANG</topic><topic>Cystic Fibrosis - blood</topic><topic>ENFANT</topic><topic>ENFERMEDADES HEPATICAS</topic><topic>FIBROMA</topic><topic>FIBROME</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>MALADIE DU FOIE</topic><topic>MALNUTRICION</topic><topic>MALNUTRITION</topic><topic>Medical sciences</topic><topic>NINOS</topic><topic>NUTRI</topic><topic>Other diseases. Semiology</topic><topic>PIRIDINAS</topic><topic>PYRIDINE</topic><topic>Pyridoxal Phosphate - blood</topic><topic>r)PIRIDOXINA</topic><topic>Time Factors</topic><topic>Veins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Faraj, B.A</creatorcontrib><creatorcontrib>Caplan, D.B</creatorcontrib><creatorcontrib>Camp, V.M</creatorcontrib><creatorcontrib>Pilzer, E</creatorcontrib><creatorcontrib>Kutner, M</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Faraj, B.A</au><au>Caplan, D.B</au><au>Camp, V.M</au><au>Pilzer, E</au><au>Kutner, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low levels of pyridoxal 5'-phosphate in patients with cystic fibrosis</atitle><jtitle>Pediatrics (Evanston)</jtitle><addtitle>Pediatrics</addtitle><date>1986-08-01</date><risdate>1986</risdate><volume>78</volume><issue>2</issue><spage>278</spage><epage>282</epage><pages>278-282</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><coden>PEDIAU</coden><abstract>Extract: To determine the effect of cystic fibrosis on the regulation of plasma pyridoxal 5'-phosphate (PLP), the biologically active form of vitamin B6, we measured this compound in plasma from 56 patients with cystic fibrosis. The concentration of PLP in plasma was assayed by a radioenzymatic technique. The results of this study showed that PLP concentration was decreased significantly (6.44 +/- 5.20 ng/mL, mean +/- SD; median 4.45 ng/mL) in patients with cystic fibrosis as compared with a group of hospitalized children with neither cystic fibrosis nor hepatic disease serving as a control group (13.2 +/- 5.04 ng/mL, mean +/- SD; median 12.5 ng/mL). Additionally, 25% of the population with cystic fibrosis exhibited exceedingly low plasma PLP level (less than 2.75 ng/mL). In patients with cystic fibrosis, significant inverse linear associations were found between plasma PLP1018 and serum levels of SGOT and SGPT (PLP v SGOT: r = -.60, P less than .03; PLP v SGPT: r = -.50, P less than .03). This study demonstrated that a deficiency of plasma PLP is a common abnormality in cystic fibrosis and that the low PLP level may be a reflection of impaired vitamin B6 metabolism associated with this disorder.(aut</abstract><cop>Elk Grove Village, IL</cop><pub>American Academy of Pediatrics</pub><pmid>3737304</pmid><doi>10.1542/peds.78.2.278</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-4005 |
| ispartof | Pediatrics (Evanston), 1986-08, Vol.78 (2), p.278-282 |
| issn | 0031-4005 1098-4275 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76972008 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Adult ADULTE ADULTOS Alanine Transaminase - blood Aspartate Aminotransferases - blood Biological and medical sciences Body Height Body Weight BPYRIDOXINE Child Child, Preschool COMPOSICION DE LA SANGRE COMPOSITION DU SANG Cystic Fibrosis - blood ENFANT ENFERMEDADES HEPATICAS FIBROMA FIBROME Follow-Up Studies Gastroenterology. Liver. Pancreas. Abdomen Humans Liver. Biliary tract. Portal circulation. Exocrine pancreas MALADIE DU FOIE MALNUTRICION MALNUTRITION Medical sciences NINOS NUTRI Other diseases. Semiology PIRIDINAS PYRIDINE Pyridoxal Phosphate - blood r)PIRIDOXINA Time Factors Veins |
| title | Low levels of pyridoxal 5'-phosphate in patients with cystic fibrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T05%3A49%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20levels%20of%20pyridoxal%205'-phosphate%20in%20patients%20with%20cystic%20fibrosis&rft.jtitle=Pediatrics%20(Evanston)&rft.au=Faraj,%20B.A&rft.date=1986-08-01&rft.volume=78&rft.issue=2&rft.spage=278&rft.epage=282&rft.pages=278-282&rft.issn=0031-4005&rft.eissn=1098-4275&rft.coden=PEDIAU&rft_id=info:doi/10.1542/peds.78.2.278&rft_dat=%3Cproquest_cross%3E76972008%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76972008&rft_id=info:pmid/3737304&rfr_iscdi=true |